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Introduction
Acute cholecystitis (AC) is a common complication of
gallstone disease and accounts for 3%to9% of all hospital
admissions for acute abdominal pain.1,2 In a systematic
review, acute cholecystitis was seen in 6 to 11 percent of
patients with symptomatic gallstones over a median
follow-up of 7 to 11 years.3 The patients with acute
cholecystitis may present with varying degree of disease
severity, usually dictated by the duration of obstruction
by gallstones and the presence of secondary infection.4
Associated co-morbid conditions may also influence the
clinical presentation, for example, diabetic patients are
more prone to develop acute gangrenous cholecystitis, as
compared to non-diabetic patients.5
The usual treatment plan for patients with acute
cholecystitis consists of antibiotics followed by surgical
intervention. The choice and duration of antibiotics
usually remain a contentious issue in this situation.
Updated Tokyo Guidelines classified the patients with
acute cholecystitis into three broad groups on the basis of
severity of infection and provide recommendations for
the antibiotic regimen and duration of therapy in each
category.6 Regarding surgical treatment, early
laparoscopic cholecystectomy is the operation of choice
for mild and moderate acute cholecystitis. For severe
cholecystitis, Tokyo Guidelines recommend draining the
gall bladder initially, and plan delayed cholecystectomy.7
The current study was conducted at a tertiary care
university hospital which was trying to follow and
implement Tokyo Guidelines for the last few years. The
current study was planned to observe changes in
surgeons' practices of antibiotic usage in patients with
acute cholecystitis, before and after the implementation
of the guidelines.
Patients and Methods
This retrospective, descriptive study was conducted at the
Department of Surgery of Aga Khan University Hospital
(AKUH), Karachi, and comprised medical records of all
patients with the diagnosis of acute calculus cholecystitis
who presented in 2009 and those who presented in 2014
after the implementation of Tokyo Guidelines. Exemption
was obtained from the institutional ethics review
committee. All adult patients who presented to our
hospital with symptoms of right upper quadrant pain and
diagnosed to have acute calculus cholecystitis on the
basis of clinical and radiological signs and underwent
cholecystectomy were included. Acute calculus
cholecystitis was finally confirmed on the basis of
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Objective: To observe changes in surgeons' practice of antibiotic usage in patients with acute cholecystitis before
and after the implementation of Tokyo Guidelines.
Methods: This retrospective, descriptive study was conducted at the Aga Khan University Hospital, Karachi, and
comprised the medical records of all patients with the diagnosis of acute calculus cholecystitis who presented in
2009 and those who presented in 2014 after the implementation of Tokyo Guidelines. The major variables included
patients' demographics, antibiotics used and surgical outcomes. SPSS 19 was used for data analysis.
Results:Of the 356 patients, 96(27%) were treated in 2009 and 260(73%) in 2014. The overall mean age was 48.9±14
years. There were 185(52%) females and 171(48%) males. Comparison of the data from 2 years showed no difference
in gender, American Society of Anaesthesiologists level, grade of acute cholecystitis and frequency of use of empiric
antibiotics (p>0.05 each). However, there was significantly less use of combination therapy (p=0.00) and
metronidazole (p=0.00) in 2014than in 2009. Interval cholecystectomy was significantly less practised in 2014
(p=0.03) resulting in shorter hospital stay (p=0.00). Despite improvement in antibiotic usage practices, post-
operative infection rates remained the same in both the groups (p=0.58).
Conclusion: Implementation of Tokyo Guidelines not only greatly influenced but also standardised the choice of
antibiotics in patients without compromising the infective and surgical outcomes.
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histopathology. Patients with incomplete data and a
calculus cholecystitis were excluded. Education regarding
Tokyo Guidelines and its implementation was started in
2010 in our hospital. Tokyo Guidelines were last updated
in 2013, so to assess the accurate outcomes and change in
our practices we selected patients before implementation
of Tokyo Guidelines (year 2009) in our set-up and
compared them with the patients after the
implementation and upgrading of Tokyo Guidelines (year
2014). During this period, the general surgery faculty
members and residents at our hospital were repeatedly
educated in evidence-based and core curriculum
sessions, morbidity and mortality meetings and grand
round presentations regarding Tokyo Guidelines and its
implications.
A detailed proforma was developed to record information
on patient's demographics, clinical features,
haematological and radiological investigations, empiric
antibiotics used (monotherapy — single antibiotic,
combination therapy — more than one antibiotic) and
sensitivity of organisms found in bile or gallbladder tissue
cultures. Patients were classified into grade I, II and III
according to Tokyo Guidelines on the basis of severity of
disease (Table-1), and our practices of antibiotic usage
were compared. Post-operative 30-day infective
morbidity (surgical site infection, intra-abdominal
abscess, and urinary tract and chest infections) was also
recorded. Data regarding type of surgical intervention
(laparoscopic or open cholecystectomy) and time of
surgical intervention (early or delayed cholecystectomy)
was also collected. With increasing experience in
laparoscopy, the same admission laparoscopic
cholecystectomy was offered for all grades of acute
cholecystitis in our centre, and only a few patients
underwent delayed cholecystectomy (i.e. after 6 weeks of
conservative management and very a small number of
them were managed with cholecystostomy tube). A four-
port laparoscopic cholecystectomy was attempted in all
patients in the year 2014 and a majority of patients in the
year 2009 except for a few (in whom open
cholecystectomy was preferred due to increase body
mass index (BMI) or previous surgery or surgeon's
preference). Unclear anatomy of Calot's triangle and
dense adhesions were the major factors for conversion
from laparoscopic to open cholecystectomy in our set-up.
SPSS 19 was used for data analysis. Quantitative variables
were reported as means ±standard deviations or median
±interquartile range (IQR), depending upon distribution
of data. Qualitative variables were reported as
proportions and percentages. Association of qualitative
variables was analysed using chi-square test, whereas
association of quantitative variables was analysed by t-
test. For more than two quantitative variables, one-way
analysis of variance (ANOVA) test was used. P<0.05 was
considered significant.
Results
Of the 356 patients admitted during these 2 non-
consecutive years, 185(52%) were females and 171(48%)
were males. The overall mean age was 48.9±14.1 years. As
per Tokyo Guidelines, 142(40%) patients were classified as
having grade I, 185(52%) as grade II and 29(8%) as grade
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Table-1: Descriptive data.
Severity Grading for Acute Cholecystitis, According to Tokyo Guidelines
Grade I (mild)
Grade II (moderate)
Grade III (severe)
PT-INR: Prothrombin time - international normalised ratio.
Does not meet the criteria of ''Grade III'' or ''Grade II'' acute cholecystitis.
Grade I can also be defined as acute cholecystitis in a healthy patient with no organ dysfunction and mild inflammatory changes in the gallbladder, making
cholecystectomy a safe and low-risk operative procedure
Associated with any one of the following conditions:
1. Elevated white blood cell count (> 18,000 cells per cubic millimetre)
2. Palpable tender mass in the right upper abdominal quadrant
3. Duration of complaints > 72 hours
4. Marked local inflammation (gangrenous cholecystitis, pericholecystic abscess, hepatic abscess, biliary peritonitis, emphysematous cholecystitis)
Associated with dysfunction of any one of the following organs/systems:
1. Cardiovascular dysfunction Hypotension requiring treatment with dopamine > 5 µg/kg per min, or any dose of norepinephrine
2. Neurological dysfunction Decreased level of consciousness
3. Respiratory dysfunction PaO2/FiO2 ratio < 300
4. Renal dysfunction Oliguria, creatinine> 2.0 mg/dl
5. Hepatic dysfunction PT-INR >1.5
6. Haematological dysfunction Platelet count < 100,000/mm3
III cholecystitis. Of patients with severe acute cholecystitis
(i.e. > grade II), 12(41.4%) had American Society of
Anaesthesiologists (ASA) level of more than 2, compared
to 12(8.5%) and 41(22.2%) of patients in mild (grade I) and
moderate (grade II) acute cholecystitis, respectively
(Table-2).
Empiric antibiotics were used in 349(97%) patients,
including combination therapy in 182(52.1%) patients
and monotherapy in 167(47.9%) patients. Most of the
patients with severe acute cholecystitis received
combination therapy, while monotherapy was more
frequently used in patients with mild and moderate acute
cholecystitis. Besides, 201(56.5%) patients also received
antibiotics on discharge, including 55(38.7%) in grade I,
122(65.9%) in grade II and 24(82.8%) in grade III (Table-3).
Laparoscopic cholecystectomy was performed on
137(96.5%), 162(87.6%) and 19(65.5%) patients in grade I,
II and III, respectively. Overall, 319(89.6%) patients
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Table-2: Descriptive data.
Variable Grade I N=142 Grade II N=185 Grade III N=29 p value
n (%) n (%) n (%)
Age, mean (SD), y 46.7 ± 14.8 49.7 ± 13.8 55.1 ± 14.2 0.193
Gender
Male 63 (44) 93 (50.3) 15 (51.7) 0.524
Female 79 (56) 92 (49.7) 14 (48.3)
Co-morbids 56 (39.4) 97 (52.4) 19 (65.5) 0.010
DM II 21 (14.8) 54 (29.2) 14 (48.3)
Hypertension 43 (30.3) 67 (36.2) 15 (51.7)
Ischaemic Heart Disease 7 (4.9) 14 (7.6) 1 (3.4)
ASA Level
II or less 130 (91.5) 144 (77.8) 17 (58.6) 0.000
> II 12 (8.5) 41 (22.2) 12 (41.4)
Hospital Stay 0.000
48 hours or less 108 (76.1) 102 (55.1) 7 (24.1)
> 48 hours 34 (23.9) 83 (44.9) 22 (75.9)
SD: Standard deviation
DM: Diabetes mellitus
ASA: American Society of Anaesthesiologists.
Table-3: Use of antibiotics.
Variable Grade I N=142 Grade II N=185 Grade III N=29 p value
n (%) n (%) n (%)
Empiric Antibiotic Used
Yes 136 (95.8) 184 (99.5) 29 (100) 0.043
No 6 (4.2) 1 (0.5) 0 (0)
Combination Therapy 52 (36.6) 105 (56.8) 25 (86.2) 0.000
Monotherapy 84 (59.2) 79 (42.7) 4 (13.8) 0.000
Combination Therapy
Ceftriaxone + Meronidazole 23 (16.2) 63 (34.1) 13 (44.8)
Ceftriaxone + Meronidazole + Ampicillin 20 (14.1) 24 (12.9) 4 (13.8)
Others 9 (6.3) 18 (9.8) 8 (27.6)
Monotherapy or No antibiotic 90 (63.4) 80 (43.2) 4 (13.8)
Monotherapy
Ceftriaxone 35 (24.6) 51 (27.6) 4 (13.8)
Cefazolin 49 (34.5) 25 (13.5) 0 (0)
Ciprofloxacin 0 (0) 2 (1.1) 0 (0)
Combination therapy or No antibiotic 58 (40.9) 107 (57.8) 25 (86.2)
Use of Metronidazole 49 (34.5) 95 (51.4) 18 (62.1) 0.002
Antibiotic on discharge 55 (38.7) 122 (65.9) 24 (82.8) 0.000
For categorical variables chi-square test was used.
underwent cholecystectomy in the same admission while
interval cholecystectomy was performed in
37(10.4%)patients, being highest in grade III acute
cholecystitis, i.e. 6(20.7%). Conversion rate from
laparoscopic to open cholecystectomy was 32(9%), being
highest 9(31%) in grade III and lowest 4(2.8%) in grade I
acute cholecystitis. Overall, 30-day post-operative
infective complications were seen in 18(5%) patients;
surgical site infection was most common at 14(3.9%)
(Table-4).
Year-wise analysis showed that the total number of
patients with acute cholecystitis was 96(27%) in the year
2009 and 260(73%) in the year 2014. The comparison of
the data from 2 years showed no significant difference in
gender, ASA level, grade of acute cholecystitis, use of
empiric antibiotics in hospital and percentage of patients
receiving antibiotics on discharge in 2 groups. However,
there was a significant difference in the use of
combination therapy (114(43.8%) in 2014 vs. 67(69.8%) in
2009, p=0.00), monotherapy (142(54.6%) in 2014 vs.
26(27.1%) in 2009, p=0.00) and metronidazole (98(37.7%)
in 2014 vs. 64(66.7%) in 2009, p=0.00) (Table-5).
On comparing surgical outcomes between these two
years, significantly more patients underwent laparoscopic
cholecystectomy in 2014 (241(92.7%) in 2014 vs.
77(80.2%) in 2009, p=0.00), while conversion from
laparoscopic to open cholecystectomy was comparatively
less in 2014 (19(7.3%) in 2014 vs. 13(13.5%) in 2009,
J Pak Med Assoc
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Table-4: Surgical data.
Variable Grade I N=142 Grade II N=185 Grade III N=29 p value
n (%) n (%) n (%)
Type of Cholecystectomy 0.000
Laparoscopic Cholecystectomy 137 (96.5) 162 (87.6) 19 (65.5)
Lap. converted to Open Cholecystectomy 4 (2.8) 19 (10.3) 9 (31)
Open Cholecystectomy 1 (0.7) 4 (2.2) 1 (3.4)
Time of Cholecystectomy 0.010
Same admission/early Cholecystectomy 135 (95.1) 161 (87) 23 (79.3)
Interval Cholecystectomy 7 (4.9) 24 (13) 6 (20.7)
Postoperative morbidity 0.046
Wound infection 4 (2.8%) 8 (4.3%) 2 (6.9%)
Intra-abdominal abscess 0 2 (1.1%) 1 (3.4%)
Chest infection 0 0 1 (3.4%)
For categorical variables chi - square test was used.
Table-5: Comparison of two years (2009 vs. 2014).
Variable 2014 N=260 2009 N=96 p value
n (%) n (%)
Age, mean (SD), y 48.0 ± 14.0 51.4 ± 14.4 0.03
Gender
Male 119 (45.8) 52 (54.2) 0.18
Female 141 (54.2) 44 (45.8)
ASA Level
II or less 218 (83.8) 74 (77.1) 0.16
> II 42 (16.2) 22 (22.9)
Grade of Acute Cholecystitis
Mild 102 (39.2) 40 (41.7) 0.38
Moderate 135 (52) 50 (52) 0.53
Severe 23 (8.8) 6 (6.3) 0.51
Empiric Antibiotic Used
Yes 256 (98.5) 93 (96.9) 0.28
No 4 (1.6) 3 (3.1)
Combination Therapy 114 (43.8) 67 (69.8) 0.00
Monotherapy 142 (54.6) 26 (27.1) 0.00
Use of Metronidazole 98 (37.7) 64 (66.7) 0.00
Antibiotic on discharge 142 (54.6) 59 (61.5) 0.27
SD: Standard deviation
ASA: American Society of Anaesthesiologists.
Table-6: Comparison of two years — Operative outcomes.
Variable 2014 N=260 2009 N=96 p value
n (%) n (%)
Type of Cholecystectomy
Laparoscopic Cholecystectomy 241 (92.7) 77 (80.2) 0.00
Lap. converted to Open Cholecystectomy 19 (7.3) 13 (13.5) 0.09
Open Cholecystectomy 0 (0) 6 (6.3) 0.00
Time of Cholecystectomy
Same admission/early Cholecystectomy 239 (91.9) 80 (83.3) 0.03
Interval Cholecystectomy 21 (8.1) 16 (16.7) 0.03
Hospital Stay
48 hours or less 178 (68.5) 39 (40.6) 0.00
> 48 hours 82 (31.5) 57 (59.4) 0.00
Post-operative morbidity 12 (4.6%) 6 (6.3%) 0.58
Wound infection 9 (3.5%) 5 (5.2%) 0.53
For categorical variables chi-square test was used.
p=0.09). Interval cholecystectomy was significantly less
practised in 2014 (21(8.1%) in 2014 vs. 16(16.7%) in 2009,
p=0.03). A significantly shorter hospital stay was noticed
in 2014 (178(68.5%) in 2014 had a hospital stay of less
than 48 hours vs. 39(40.6%) in 2009, p=0.00). Post-
operative infective complications rate was not different
between these two years (12(4.6%) in 2014 vs. 6(6.3%) in
2009, p=0.58) (Table-6).
Bile or gall bladder cultures were sent in 166(46.6 %)
patients and 78(46.9%) were positive for bacterial growth.
The most common bacteria found were Escherichia coli
45(57.7%), Streptococcus 13(16.6%), Klebsiella 7(9%) and
Enterococci 5(6.5%).
Discussion
After implementing Tokyo Guidelines, overall use of
combination therapy has significantly reduced (from
69.8% in 2009 to 43.8% in 2014, p=0.00). In 2009, 62.5%
patients with grade I acute cholecystitis received a
combination of two or three antibiotics, whereas in 2014
the use of combination therapy for same grade of acute
cholecystitis significantly dropped to 26.5%. Similarly in
grade II acute cholecystitis, the use of monotherapy was
becoming more frequent and combination therapy
dropped from 74% to 49.6%.
Ceftriaxone (53.9%) was the most common antibiotic
used as monotherapy, followed by cefazolin (44.3%).
According to updated Tokyo Guidelines, ceftriaxone and
cefazolin can be used as montherapy for grade I and II
acute cholecystitis. In grade III acute cholecystitis, more
than 80% patients received combination therapy in both
years, with no significant difference. However, the
difference was in the choice of antibiotics used. In 2009,
most common combination therapy included three drugs
(ceftriaxone, ampicillin andmetronidazole) with rationale
of covering gram-negative, gram-positive and anaerobic
organisms. However, after following Tokyo Guidelines,
ceftriaxone + metronidazole (56.5%) was the most
common combination, followed by piperacillin/
tazobactam + metronidazole (17.4%) and imipenem +
metronidazole (4.3%).
As per Tokyo Guidelines, piperacillin/tazobactam is the
first antibiotic of choice for grade III acute cholecystitis.
Alternate recommendations are cefepime, ceftazidime or
cefozopran with or without metronidazole. In our study,
the practice of using ceftriaxone in grade III acute
cholecystitis can be partly attributed to the high cost of
other alternative drugs. The most common dosage of
ceftriaxone used in our set-up is 2 grams quaquedie (QD)
(approximately 5.25 dollars), whereas the dosage of
piperacillin/tazobactam is 4.5 grams ter in die (TID)
(approximately 23.7 dollars). Also on the basis of our
culture and sensitivity data, the overall sensitivity of
ceftriaxone against Escherichia coli was 77.8%. However,
on further analysis it was noticed that its sensitivity
dropped from almost 88.9% in 2009 to nearly 70.4% in
2014. The final draft of the updated Tokyo Guidelines
(TG13) recommendations for grade III acute cholecystitis
are based on the concept that in severe acute
cholecystitis, polymicrobial gram-negative and anaerobes
or multi-drugs resistant microorganisms are present,
including Pseudomonas. In our population,
Pseudomonades were not isolated from any cultures of
patients with grade III cholecystitis.
According to Tokyo Guidelines, metronidazole should be
used only in patients who have biliary-enteric
anastomosis or if the other antibiotic has poor anaerobic
coverage.8 In our study, metronidazole was used
empirically not only in grade III (62.1%) but also in grade I
(34.5%) and grade II (51.4%) acute cholecystitis. After
implementation of TG13, the use of metronidazole
dropped significantly in grade I (from 62.5% in 2009 to
23.5% in 2014) and grade II acute cholecystitis (from 70%
in 2009 to 44.4% in 2014).
For definitive surgical options, TG13 clearly recommends
early laparoscopic cholecystectomy for grade I and II
acute cholecystitis.7 In this study, early cholecystectomy
was performed successfully in 95.1% and 87% patients
with grade I and II cholecystitis.
For grade III acute cholecystitis, TG13 recommends
delayed cholecystectomy, once the local and systemic
inflammation is in control. Gall bladder drainage should
be done for control of local inflammation. In our
experience, almost 79.3% patients with grade III acute
cholecystitis underwent early cholecystectomy. However,
conversion rate from laparoscopic to open
cholecystectomy was pretty high (31%) in grade III as
compared to grade I and II combined (7%). A number of
recently published studies and trials have proved the
safety and efficacy of early cholecystectomy in patients
with grade III acute cholecystitis or in critically ill
patients.9-12 Similarly, a recent review found no evidence
to support the recommendation of percutaneous
drainage rather than straight early emergency
cholecystectomy, even in critically ill patients. This is
based on the data that suggests the mortality rate after
percutaneous cholecystostomy tube drainage (15.4%) is
significantly higher than reported after early
cholecystectomy (4.5%).13 With experience, early
cholecystectomy increased significantly in all grades in
our set-up (from 83.3% in 2009 to 91.9% in 2014, p=0.03).
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Regarding duration of antibiotic treatment, TG13
recommends that for grade I acute cholecystitis
antimicrobial therapy can be discontinued within 24
hours after cholecystectomy is performed. For grade II
and III acute cholecystitis, recommendation is to give
antibiotics for 4-7 days, once source of infection is
controlled. In our study it was observed that almost 38.7
% patients with grade I acute cholecystitis received
antibiotics, after cholecystectomy. A significant drop was
observed in this trend after implementation of TG13 (from
57.5% in 2009 to 31.4% in 2014). Nearly 65.9% and 82.8%
patients of grade II and III cholecystitis, respectively,
received antibiotics after cholecystectomy.
Although significant reduction was noticed in the use of
combination therapy, no change in infective morbidity
rate was noticed over the years (from 6.3% in 2009 to 4.6%
in 2014, p=0.58). This suggests that antibiotics may have a
limited role in preventing post-operative surgical site or
distant site infection. There are multiple trials14-17 showing
that peri-operative use of antibiotics in grade I and grade II
acute cholecystitis does not have any role in preventing
surgical site or systemic infections. However, Tokyo
Guidelines still recommend the use of antibiotics in these
patients. At the same time there are reports in current
literature which show the limitations of TG13 with respect
to the grading of severity of acute cholecystitis on the
basis of which antibiotics are recommended. For example,
a study from Germany suggests that Tokyo Guidelines
might underestimate the level of gallbladder
inflammation in patients with grade I acute cholecystitis.18
In general, inappropriate use of antibiotics not only
increases the risk of bacterial resistance, but it has a
detrimental effect on the cost as well.19,20 If patients with
mild and moderate acute cholecystitis can undergo
surgery without peri-operative antibiotics, it will reduce
the chances of microbial resistance, lessen the hospital
charges21,22 and also decrease the incidence of allergic or
worse reactions caused by antibiotics.23 However, to
ascertain that peri-operative antibiotics in mild and
moderate acute cholecystitis do not affect the rate of
surgical site infection or distant infection, a randomised
study is required in our set-up.
It will also be interesting to look for the chances of
infective complications in patients, who had intra-
operative bile spillage, as nearly 50% of bile or tissue
cultures sent in this study and reported in other
population were positive for bacterial growth.24 Also, the
antibiotic practice may be influenced in critically ill
patients (ASA III/IV) in whom recent studies suggests that
they are at increased risk for extensive gallbladder
inflammation with higher chances of morbidity and
mortality as compared to otherwise healthy patients
(ASAI/II).25
Conclusion
Implementation of Tokyo Guidelines effectively changed
the surgeons' practices. It improved and simplified the
selection of empirical antibiotic in patients with acute
calculous cholecystitis, without compromising the
surgical outcomes or post-operative infective morbidity.
There is a need to explore further strategies to reduce the
cost and antibiotic resistance.
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